Search Results - "Nasonov , E. L."

Anti-Carbamylated Protein Antibodies in ACPA-Negative and ACPA-Positive Patients with Rheumatoid Arthritis by Dibrov, D. A., Avdeeva, A. S., Diatroptov, M. E., Nasonov, E. L.

“…The objective of this study was to assess the level of antibodies to carbamylated proteins and analyze the clinical and immunological associations in patients…”
Get full text

New directions of pharmacotherapy of immune - inflammatory rheumatic diseases by Nasonov, E L

“…Deciphering immunopathogenesis, expanding the scope of diagnostics and developing new methods for treating human autoimmune diseases are among the priority…”
Get full text

Clinical Features of ACPA-Negative and ACPA-Positive Variants of Rheumatoid Arthritis by Dibrov, D. A., Avdeeva, A. S., Rybakova, V. V., Demidova, N. V., Nasonov, E. L.

“…The aim of the study was to investigate the features of the clinical picture of the disease in patients with ACPA–negative and ACPA-positive variants of…”
Get full text

The Prevalence and Factors Associated with Coronary Heart Disease in Patients with Gout by Markelova, E. L., Eliseev, M. S., Il’inykh, E. V., Glukhova, S. I., Nasonov, E. L.

“…Gout is associated with increased risk of cardiovascular disease (CVD) morbidity and mortality. Therefore, an association between coronary heart disease (CHD)…”
Get full text

Atherosclerosis: perspectives of anti-inflammatory therapy by Nasonov, E L, Popkova, T V

“…According to modern ideas, chronic low-grade inflammation, which development is associated with uncontrolled activation of both innate and adaptive immunity,…”
Get full text

Rheumatoid arthritis: achievements and unresolved issues by Nasonov, E L, Lila, A M

“…Success in a treatment of rheumatoid arthritis (RA), associated with a development of new medications and improving treatment strategies, allows to achieve…”
Get full text

Efficacy and Safety of Levilimab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: 56-Week Results of Phase III Randomized Double-Blind Placebo-Controlled Trial SOLAR by Mazurov, V. I., Nasonov, E. L., Lila, A. M., Korolev, M. A., Prystrom, A. M., Kundzer, E. V., Soroka, N. F., Kastanayan, A. A., Povarova, T. V., Plaksina, T. V., Antipova, O. V., Krechikova, D. G., Smakotina, S. A., Tciupa, O. A., Puntus, E. V., Raskina, T. A., Shilova, L. N., Kropotina, T. V., Nesmeyanova, O. B., Popova, T. A., Vinogradova, I. B., Dokukina, E. A., Plotnikova, A. V., Pukhtinskaia, P. S., Zinkina-Orikhan, A. V., Linkova, Yu. N., Eremeeva, A. V., Lutckii, A. A.

“…—Background . Previously, 24-week results of phase III double-blind, placebo-controlled randomized clinical study (SOLAR) of levilimab in subjects with active…”
Get full text

Prospects for rheumatoid arthritis pharmacotherapy: New opportunities and recommendations by Nasonov, E L

“…The paper considers a current strategy, international and Russian recommendations for the pharmacotherapy of rheumatoid arthritis (RA), one of the most common…”
Get full text

Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout by Panevin, T. S., Eliseev, M. S., Shestakova, M. V., Nasonov, E. L.

“…Currently, only two drugs for reducing uric acid (UA), allopurinol and febuxostat, are registered in the Russian Federation, but their use does not allow to…”
Get full text

The use of Tofacitinib in the treatment of inflammatory bowel disease by Nasonov, E L, Abdulganieva, D I, Fairushina, I F

“…Major advances in pharmacology of the 21st century include the development of a new class of drugs, which are low-molecular, chemically synthesized molecules…”
Get full text

PROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES by Nasonov, E L., Beketova, T. V., Ananyeva, L. P., Vasilyev, V. I., Solovyev, S. K., Avdeeva, A. S.

“…Impaired B-cell immunological tolerance plays a central role in the pathogenesis of immuno-inflammatory rheumatic diseases (IIRD). B-cells link innate and…”
Get full text

Depression and severity of articular destruction in patients with rheumatoid arthritis by Abramkin, A. A., Lisitsyna, T. A., Veltishchev, D. Yu, Seravina, O. F., Kovalevskaya, O. B., Glukhova, S. I., Nasonov, E. L.

“…Aim. To assess the influence of anxiety and depressive disorders on joint destruction in patients with rheumatoid arthritis (RA). Materials and methods. 128…”
Get full text

Coronavirus disease 2019 (COVID-19) pandemic and autoimmune rheumatic diseases: Outcomes and prospects by Nasonov, E. L.

“…The pandemic of coronavirus disease 2019 (COVID-19), etiologically related to the SARS-CoV-2 virus (severe acute respiratory syndrome coronavirus-2), has drawn…”
Get full text

Modern concept of autoimmunity in rheumatology by Nasonov, E. L.

“…Two fundamental pathologic processes are central to the spectrum of chronic inflammation mechanisms: autoimmunity and autoinflammation. Autoimmunity and…”
Get full text

Effectiveness and safety of selective and non - selective factor Xa inhibitors in antiphospholipid syndrome and systemic lupus erythematosus: anti - Xa - activity range by Seredavkina, N V, Reshetnyak, T M, Satybaldyeva, M A, Kashnikova, L N, Temnikova, T A, Nasonov, E L

“…The aim of the study was to evaluate the anti - Xa - activity (aXa) of selective and non - selective factor Xa inhibitors in patients with systemic lupus…”
Get full text

Rheumatology in Russia in the early 21st century by Nasonov, E L

“…Rheumatoid arthritis (RA) is the most common immune inflammatory rheumatic disease. The paper gives the current data of Russian investigations into the early…”
Get full text

Chronic pain and depression in patients with rheumatoid arthritis: results of five - year follow - up by Lisitsyna, T A, Abramkin, A A, Veltishchev, D Yu, Seravina, O F, Kovalevskaya, O B, Zeltyn, A E, Glukhova, S I, Nasonov, E L, Krasnov, V N

“…The aim of the study was to analyze the factors affecting chronic pain in patients with rheumatoid arthritis (RA). Materials and methods. 128 patients with…”
Get full text

Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study by Korotaeva, T V, Loginova, E Yu, Getiya, T S, Nasonov, E L

“…To study efficacy of treat-to-target (T2T) strategy in early peripheral psoriatic arthritis (EPsA) after one year of treatment. 44 (M/F - 18/26) DMARD-naїve…”
Get full text

The role of laboratory biomarkers in monitoring of rituximab biosimilar therapy (Acellbia, “BIOCAD”) in patients with rheumatoid arthritis by Avdeeva, A S, Cherkasova, M V, Kusevich, D A, Rybakova, V V, Artyuhov, A S, Dashinimaev, Eh B, Chichasova, N V, Nasonov, E L

“…Aim: to evaluate the role of laboratory biomarkers in monitoring effectiveness of rituximab (RTM) biosimilar therapy in a total dose of 1200 mg. Materials and…”
Get full text

Cardiovascular disease in rheumatic diseases by Nasonov, E L, Popkova, T V, Novikova, D S

“…The representatives of immunoinflammatory diseases are rheumatic ones, such as primarily rheumatoid arthritis, juvenile idiopathic arthritis,…”
Get full text